These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 28739156)

  • 21. Synthesis, screening and computational investigation of pentacycloundecane-peptoids as potent CSA-HIV PR inhibitors.
    Makatini MM; Petzold K; Arvidsson PI; Honarparvar B; Govender T; Maguire GE; Parboosing R; Sayed Y; Soliman ME; Kruger HG
    Eur J Med Chem; 2012 Nov; 57():459-67. PubMed ID: 22867528
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
    Jadhav PK; Ala P; Woerner FJ; Chang CH; Garber SS; Anton ED; Bacheler LT
    J Med Chem; 1997 Jan; 40(2):181-91. PubMed ID: 9003516
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and activity of N-benzyl pseudopeptides HIV protease inhibitors.
    Marastoni M; Bazzaro M; Bortolotti F; Tomatis R
    Bioorg Med Chem; 2003 May; 11(11):2477-83. PubMed ID: 12735995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, biologic evaluation, and SAR of novel pseudo-peptide incorporating benzheterocycles as HIV-1 protease inhibitors.
    He M; Zhang H; Yao X; Eckart M; Zuo E; Yang M
    Chem Biol Drug Des; 2010 Aug; 76(2):174-80. PubMed ID: 20572811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses.
    Arodola OA; Soliman ME
    Drug Des Devel Ther; 2015; 9():6055-65. PubMed ID: 26622167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design and synthesis of potent HIV-1 protease inhibitors with (S)-tetrahydrofuran-tertiary amine-acetamide as P2-ligand: Structure-activity studies and biological evaluation.
    Bai X; Yang Z; Zhu M; Dong B; Zhou L; Zhang G; Wang J; Wang Y
    Eur J Med Chem; 2017 Sep; 137():30-44. PubMed ID: 28554091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insight into the structural similarity between HIV protease and secreted aspartic protease-2 and binding mode analysis of HIV-Candida albicans inhibitors.
    Calugi C; Guarna A; Trabocchi A
    J Enzyme Inhib Med Chem; 2013 Oct; 28(5):936-43. PubMed ID: 22803674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, asymmetric synthesis, and evaluation of pseudosymmetric sulfoximine inhibitors against HIV-1 protease.
    Lu D; Sham YY; Vince R
    Bioorg Med Chem; 2010 Mar; 18(5):2037-48. PubMed ID: 20138769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Switching between allosteric and dimerization inhibition of HIV-1 protease.
    Bowman MJ; Byrne S; Chmielewski J
    Chem Biol; 2005 Apr; 12(4):439-44. PubMed ID: 15850980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of HIV-1 protease by a boron-modified polypeptide.
    Pivazyan AD; Matteson DS; Fabry-Asztalos L; Singh RP; Lin PF; Blair W; Guo K; Robinson B; Prusoff WH
    Biochem Pharmacol; 2000 Oct; 60(7):927-36. PubMed ID: 10974201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere.
    Beaulieu PL; Wernic D; Abraham A; Anderson PC; Bogri T; Bousquet Y; Croteau G; Guse I; Lamarre D; Liard F; Paris W; Thibeault D; Pav S; Tong L
    J Med Chem; 1997 Jul; 40(14):2164-76. PubMed ID: 9216835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oximinoarylsulfonamides as potent HIV protease inhibitors.
    Yeung CM; Klein LL; Flentge CA; Randolph JT; Zhao C; Sun M; Dekhtyar T; Stoll VS; Kempf DJ
    Bioorg Med Chem Lett; 2005 May; 15(9):2275-8. PubMed ID: 15837308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.
    Ghosh AK; Swanson LM; Cho H; Leshchenko S; Hussain KA; Kay S; Walters DE; Koh Y; Mitsuya H
    J Med Chem; 2005 May; 48(10):3576-85. PubMed ID: 15887965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.
    Ghosh AK; Kincaid JF; Walters DE; Chen Y; Chaudhuri NC; Thompson WJ; Culberson C; Fitzgerald PM; Lee HY; McKee SP; Munson PM; Duong TT; Darke PL; Zugay JA; Schleif WA; Axel MG; Lin J; Huff JR
    J Med Chem; 1996 Aug; 39(17):3278-90. PubMed ID: 8765511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular Dynamics Simulation Study of the HIV-1 Protease Inhibit ion Using Fullerene and New Fullerene Derivatives of Carbon Nanostructures.
    Barzegar A; Naghizadeh E; Zakariazadeh M; Azamat J
    Mini Rev Med Chem; 2017; 17(7):633-647. PubMed ID: 27292780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative studies on inhibitors of HIV protease: a target for drug design.
    Jayaraman S; Shah K
    In Silico Biol; 2008; 8(5-6):427-47. PubMed ID: 19374129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Revealing interaction mode between HIV-1 protease and mannitol analog inhibitor.
    Yan GW; Chen Y; Li Y; Chen HF
    Chem Biol Drug Des; 2012 Jun; 79(6):916-25. PubMed ID: 22296911
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
    Ghosh AK; Chapsal BD; Weber IT; Mitsuya H
    Acc Chem Res; 2008 Jan; 41(1):78-86. PubMed ID: 17722874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and activity of novel HIV protease inhibitors with improved potency against multiple PI-resistant viral strains.
    Duffy JL; Kevin NJ; Kirk BA; Chapman KT; Schleif WA; Olsen DB; Stahlhut M; Rutkowski CA; Kuo LC; Jin L; Lin JH; Emini EA; Tata JR
    Bioorg Med Chem Lett; 2002 Sep; 12(17):2423-6. PubMed ID: 12161148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis of P1'-functionalized macrocyclic transition-state mimicking HIV-1 protease inhibitors encompassing a tertiary alcohol.
    De Rosa M; Unge J; Motwani HV; Rosenquist Å; Vrang L; Wallberg H; Larhed M
    J Med Chem; 2014 Aug; 57(15):6444-57. PubMed ID: 25054811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.